Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6ZMI0

UPID:
PPR21_HUMAN

ALTERNATIVE NAMES:
Coiled-coil domain-containing protein 128; KLRAQ motif-containing protein 1

ALTERNATIVE UPACC:
Q6ZMI0; B7ZKY5; B7ZKY7; E1B6W7; Q2TA78; Q6ZMI6; Q8IW83; Q8J029; Q96ES8

BACKGROUND:
The regulatory subunit 21 of protein phosphatase 1, known by its alternative names Coiled-coil domain-containing protein 128 and KLRAQ motif-containing protein 1, is implicated in the modulation of PP1 activity. Its functions suggest a significant role in cellular processes such as endosomal sorting and maturation, highlighting its importance in cellular homeostasis and signaling.

THERAPEUTIC SIGNIFICANCE:
Linked to a severe neurodevelopmental disorder with symptoms including developmental delay, muscle weakness, and various brain abnormalities, the protein represents a promising target for drug discovery. The disease's association with variants affecting this gene underscores the therapeutic potential of targeting Protein phosphatase 1 regulatory subunit 21 in future treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.